8-K: Invivyd's Pemivibart Shows 84% Risk Reduction in Symptomatic COVID-19 in Phase 3 Trial

Invivyd's pemivibart demonstrated an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in an exploratory analysis of its Phase 3 CANOPY trial.

Summary

• Invivyd announced positive 180-day exploratory clinical efficacy data from its ongoing CANOPY Phase 3 clinical trial for pemivibart, a monoclonal antibody for COVID-19 pre-exposure prophylaxis.
• In immunocompetent individuals, pemivibart showed an 84% relative risk reduction in contracting symptomatic COVID-19 compared to placebo, with a 1.9% rate of symptomatic COVID-19 in the pemivibart group versus 11.9% in the placebo group.
• In immunocompromised participants, pemivibart demonstrated a 3% rate of confirmed symptomatic COVID-19 over the 180-day period.
• The safety profile of pemivibart remained consistent with previously reported data, with most adverse events being mild to moderate.
• The study was conducted during a period that included the XBB and JN.1 variant waves, suggesting the effectiveness of pemivibart against these variants.
• The PEMGARDA Fact Sheet for Healthcare Providers has been updated by the FDA to include the new 180-day exploratory clinical efficacy data.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for pemivibart, showing a significant reduction in symptomatic COVID-19. The safety profile is consistent with previous data, and the study was conducted during a period with significant variant circulation. The management commentary is also positive, indicating confidence in the product's potential. However, there are some risks associated with anaphylaxis and infusion reactions, which temper the overall sentiment slightly.

Positives

• Pemivibart showed a significant 84% relative risk reduction in symptomatic COVID-19 in immunocompetent individuals.
• The study demonstrated a low rate of symptomatic COVID-19 in both immunocompetent (1.9%) and immunocompromised (3%) groups treated with pemivibart.
• The safety profile of pemivibart remained consistent with previous data, with no new safety concerns.
• The study was conducted during a period with significant circulation of the XBB and JN.1 variants, suggesting the effectiveness of pemivibart against these variants.
• The FDA updated the PEMGARDA Fact Sheet for Healthcare Providers to include the new 180-day exploratory clinical efficacy data.

Negatives

• Anaphylaxis was observed in 4 participants (0.6%) in the immunocompromised cohort, leading to permanent discontinuation of pemivibart.
• Systemic infusion-related reactions and hypersensitivity reactions were observed in some participants, although generally mild to moderate.
• The study is an exploratory analysis, and full data will be provided in an upcoming scientific publication.

Risks

• There is a risk of anaphylaxis with pemivibart, as observed in the study.
• Systemic infusion-related reactions and hypersensitivity reactions are potential risks associated with pemivibart.
• The study is an exploratory analysis, and the full data set is pending publication.
• The effectiveness of pemivibart may be reduced against certain SARS-CoV-2 variants.
• The emergency use authorization for PEMGARDA is dependent on the ongoing declaration of a public health emergency and could be revoked.

Future Outlook

Invivyd plans to work with the FDA to integrate clinical event findings from the CANOPY trial into future mAb development work and expects to provide the full CANOPY clinical trial data in an upcoming scientific publication. The company aims to scale and democratize access to monoclonal antibodies for protection against COVID-19.

Management Comments

• Mark A. Wingertzahn, SVP of Clinical Development and Medical Affairs, stated that they are thrilled with the clinically meaningful protection shown by pemivibart.
• Marc Elia, Chairperson of the Board, noted that the data align with and fuel their broader goals of innovating new molecules and educating the clinical community on the possibility of strong protection from monoclonal antibodies.
• Cameron R. Wolfe, M.B.B.S., M.P.H., Professor of Medicine, Transplant Infectious Disease at Duke University School of Medicine, stated that the positive CANOPY clinical efficacy data is encouraging and will be helpful to clinicians in making informed decisions about PEMGARDA use.

Industry Context

This announcement is significant as it provides further evidence for the use of monoclonal antibodies in preventing COVID-19, particularly in vulnerable populations. It contrasts with the effectiveness of vaccines and highlights the potential for mAbs to play a critical role in managing the endemic virus. The study was conducted during a period with significant circulation of the XBB and JN.1 variants, making the results highly relevant to the current situation.

Comparison to Industry Standards

• The 84% relative risk reduction in symptomatic COVID-19 observed with pemivibart is a strong result compared to other monoclonal antibody studies.
• Previous studies of COVID-19 PrEP candidate mAbs were performed in populations naive to vaccination or prior infection, while the CANOPY trial was conducted in a contemporary population with prior immune exposure, making the results more relevant to the current environment.
• The study's results are particularly notable given the inclusion of the XBB and JN.1 variant waves, which were not present in earlier studies of other mAbs.
• The results are a contrast to estimated vaccine effectiveness, suggesting that mAbs may be a critical tool for managing the endemic virus.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical trial results.
• Healthcare providers may be more inclined to use PEMGARDA for pre-exposure prophylaxis in at-risk patients.
• Immunocompromised individuals and those at risk of COVID-19 may benefit from the availability of pemivibart.
• The results may lead to increased demand for PEMGARDA, potentially impacting supply chains.

Next Steps

• Invivyd plans to work with the FDA to integrate clinical event findings from the CANOPY trial into future mAb development work.
• The company expects to provide the full CANOPY clinical trial data in an upcoming scientific publication.

Key Dates

Keywords

pemivibart, COVID-19, monoclonal antibody, pre-exposure prophylaxis, CANOPY trial, immunocompromised, FDA, EUA, SARS-CoV-2, clinical trial